Citius Pharmaceuticals, Inc. cotiza a 0.49 USD y tiene una capitalización bursátil de $14M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Citius Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of critical care products. Its LYMPHIR, an FDA-approved product, is a targeted immunotherapy for the treatment of cutaneous T-cell lymphoma. The company's late-stage pipeline includes Mino-Lok, an antibiotic lock…
| Periodo | 2026-08 | 2026-05 | 2026-02 | 2025-12 |
|---|---|---|---|---|
| Real | — | $-0.95 | $-0.38 | $-0.11 |
| Estimado | $-0.36 | $-0.32 | $-0.30 | $-0.24 |
| Sorpresa | — | -196.9% | -26.7% | +54.2% |
| Métrica | CTXR | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | — | -38.6% | — |
| Net Margin | — | -33.6% | — |
| FCF Margin | — | -13.9% | — |
| ROE | -55.4% | -40.4% | -15.0% |
| ROA | -28.6% | -32.0% | +3.4% |
| Current Ratio | 0.62 | 2.84 | -2.22 |
| Debt / Equity | — | 0.28 | — |